Shares in Transgene SA dropped 13 percent last week on news that the oncolytic immunotherapy Pexa-Vec (JX-594, pexastimogene devacirepvec) failed to attain the primary endpoint of overall survival in a Phase IIb trial in 80 patients with advanced liver cancer.